

SMBers rolle i å fylle implementeringsgapet innen AI og helse




Esten H. Leonardsen

Post-doktor ved Psykologisk Institutt,
Universitetet i Oslo


Vitenskapelig ansvarlig, baba.vision




**UNIVERSITETET
I OSLO**




Implementeringsgapet



Bilde generert av ChatGPT




Implementeringsgapet




Wang, Y., Gao, R., Wei, T., Johnston, L., Yuan, X., Zhang, Y., ... & Alzheimer's Disease Neuroimaging Initiative. (2024). Predicting long-term progression of Alzheimer's disease using a multimodal deep learning model incorporating interaction effects. *Journal of Translational Medicine*.

Implementeringsgapet




Wang, Y., Gao, R., Wei, T., Johnston, L., Yuan, X., Zhang, Y., ... & Alzheimer's Disease Neuroimaging Initiative. (2024). Predicting long-term progression of Alzheimer's disease using a multimodal deep learning model incorporating interaction effects. *Journal of Translational Medicine*.

Implementeringsgapet




Wang, Y., Gao, R., Wei, T., Johnston, L., Yuan, X., Zhang, Y., ... & Alzheimer's Disease Neuroimaging Initiative. (2024). Predicting long-term progression of Alzheimer's disease using a multimodal deep learning model incorporating interaction effects. *Journal of Translational Medicine*.

Implementeringsgapet




Leonardsen, E. H., Persson, K., Grødem, E., Dinsdale, N., Schellhorn, T., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*.

Implementeringsgapet




Leonardsen, E. H., Persson, K., Grødem, E., Dinsdale, N., Schellhorn, T., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*.

Implementeringsgapet



Leonardsen, E. H., Persson, K., Grødem, E., Dinsdale, N., Schellhorn, T., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*.


Kunstig intelligens




Leonardsen, E. H., Persson, K., Grødem, E., Dinsdale, N., Schellhorn, T., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*.

Implementeringsgapet

Kunstig intelligens




Menneskelige forskere



Leonardsen, E. H., Persson, K., Grødem, E., Dinsdale, N., Schellhorn, T., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*.


Implementeringsgapet

27 år




Xia, T., Chartsias, A., Wang, C., Tsaftaris, S. A., & Alzheimer's Disease Neuroimaging Initiative. (2021). Learning to synthesise the ageing brain without longitudinal data. *Medical Image Analysis*.

Implementeringsgapet




Xia, T., Chartsias, A., Wang, C., Tsaftaris, S. A., & Alzheimer's Disease Neuroimaging Initiative. (2021). Learning to synthesise the ageing brain without longitudinal data. *Medical Image Analysis*.


Implementeringsgapet



Implementeringsgapet



Prediksjon av behandlingsrespons



Figur 4 Antall personer med demens i Norge.

Gjøra L, Kjelvik G., Strand B.H., Kvello-Alme M. & Selbæk G. (2020) Forekomst av demens i Norge. *Rapport Aldring og helse*.


Prediksjon av behandlingsrespons



The image shows a white box and a glass vial of LEQEMBI (lecanemab-inmb) injection. The box is labeled with 'NDC: 62855-215-01', 'Rx only', '5 vial per Carton', 'Discard unused portion.', the LEQEMBI logo, '(lecanemab-inmb) Injection', '500 mg/5 mL (100 mg/mL)', and 'For intravenous infusion. Must be diluted prior to use.' The vial is labeled with 'LEQEMBI (lecanemab-inmb) Injection', '500 mg/5 mL (100 mg/mL)', and 'Single-Dose Vial Discard unused portion.'. To the right of the box and vial is a large green circle with a white checkmark inside.


European Medicines Agency reviews and revises its opinion on Lecanemab

Prediksjon av behandlingsrespons




Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*.

Prediksjon av behandlingsrespons




Villain, N., Planche, V., & Levy, R. (2022). High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. *Revue neurologique*.


Prediksjon av behandlingsrespons



Prediksjon av behandlingsrespons



Prediksjon av behandlingsrespons



Takk for oppmerksomheten!
estenhhl@uio.no



UNIVERSITETET
I OSLO

